|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ovarian Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Ovarian Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Adnexal Diseases | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Gonadal Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Ovarian Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| chromosomal translocation analysis | |||||
| comparative genomic hybridization | |||||
| laboratory biomarker analysis | |||||
| laparoscopy | |||||
| microsatellite instability analysis | |||||
| mutation analysis | |||||
| ovarian Papanicolaou test | |||||
| study of high risk factors | |||||
| 5 | Sponsors listed in this trial | ||||
| Robert H. Lurie Cancer Center | |||||
| National Cancer Institute (NCI) | |||||